Condition: Kidney Disease

A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD

Location(s): St. Augustine

Condition: Heart / Cardiovascular Disease, Kidney Disease, Overweight / Obesity

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Location(s): Jacksonville (Headquarters)

Condition: Heart / Cardiovascular Disease, Kidney Disease